曲唑酮对勃起功能障碍:系统回顾和荟萃分析。

文章的细节

引用

复制到剪贴板

芬克哈,麦克唐纳R, Rutks IR,必TJ

曲唑酮对勃起功能障碍:系统回顾和荟萃分析。

北大Int。2003年9月,92 (4):441 - 6。

PubMed ID

12930437 (在PubMed

]

文摘

目的:确定疗效和安全性的曲唑酮治疗勃起功能障碍(ED)的荟萃分析。方法:使用的数据源是Medline和Cochrane图书馆数据库(1966年1月至2002年5月),参考书目检索的文章和评论文章、会议论文集和抽象。试验都有资格列入评审是否包括男性、曲唑酮与控制相比,随机,> = 7天的持续时间和临床相关的评估结果。两个评论者独立评估研究质量和标准化的方式提取的数据。结果:6个试验(包括396名男性)满足入选标准;他们由异质种群小,短暂的,在某些情况下十分薄弱。3的6试验显示一个明显临床有意义的好处ED的曲唑酮与安慰剂相比,在两个具有统计学差异。在集中的结果,曲唑酮单一疗法似乎比安慰剂更容易导致积极的治疗反应,尽管这种差异没有统计学意义(37% vs 20%;相对效益增加,1.6;95%置信区间,CI, 0.8 - -3.3)。 Subgroup analyses suggested that men with psychogenic ED might be more likely to benefit from trazodone than those with mixed or physiological ED. The efficacy of trazodone also appeared greater at higher doses (150-200 vs 50 mg/day). Men randomized to trazodone were not significantly more likely than those receiving placebo to withdraw for any reason or for an adverse event, or to have specific adverse events, but wide CIs could not exclude a greater risk of these adverse outcomes with trazodone. Specific adverse events with trazodone included dry mouth (19%), sedation (16%), dizziness (16%) and fatigue (15%). CONCLUSION: Trazodone may be helpful in men with ED, possibly more so at higher doses, and in men with psychogenic ED. Future high-quality trials should compare trazodone with placebo and other therapies in men with depression and psychogenic ED.

DrugBank数据引用了这篇文章

药物

曲唑酮